GM2-gangliosidosis, AB variant

	WikiDoc Resources for GM2-gangliosidosis, AB variant
Articles
Most recent articles on GM2-gangliosidosis, AB variant Most cited articles on GM2-gangliosidosis, AB variant Review articles on GM2-gangliosidosis, AB variant Articles on GM2-gangliosidosis, AB variant in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on GM2-gangliosidosis, AB variant Images of GM2-gangliosidosis, AB variant Photos of GM2-gangliosidosis, AB variant Podcasts & MP3s on GM2-gangliosidosis, AB variant Videos on GM2-gangliosidosis, AB variant
Evidence Based Medicine
Cochrane Collaboration on GM2-gangliosidosis, AB variant Bandolier on GM2-gangliosidosis, AB variant TRIP on GM2-gangliosidosis, AB variant
Clinical Trials
Ongoing Trials on GM2-gangliosidosis, AB variant at Clinical Trials.gov Trial results on GM2-gangliosidosis, AB variant Clinical Trials on GM2-gangliosidosis, AB variant at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on GM2-gangliosidosis, AB variant NICE Guidance on GM2-gangliosidosis, AB variant NHS PRODIGY Guidance FDA on GM2-gangliosidosis, AB variant CDC on GM2-gangliosidosis, AB variant
Books
Books on GM2-gangliosidosis, AB variant
News
GM2-gangliosidosis, AB variant in the news Be alerted to news on GM2-gangliosidosis, AB variant News trends on GM2-gangliosidosis, AB variant
Commentary
Blogs on GM2-gangliosidosis, AB variant
Definitions
Definitions of GM2-gangliosidosis, AB variant
Patient Resources / Community
Patient resources on GM2-gangliosidosis, AB variant Discussion groups on GM2-gangliosidosis, AB variant Patient Handouts on GM2-gangliosidosis, AB variant Directions to Hospitals Treating GM2-gangliosidosis, AB variant Risk calculators and risk factors for GM2-gangliosidosis, AB variant
Healthcare Provider Resources
Symptoms of GM2-gangliosidosis, AB variant Causes & Risk Factors for GM2-gangliosidosis, AB variant Diagnostic studies for GM2-gangliosidosis, AB variant Treatment of GM2-gangliosidosis, AB variant
Continuing Medical Education (CME)
CME Programs on GM2-gangliosidosis, AB variant
International
GM2-gangliosidosis, AB variant en Espanol GM2-gangliosidosis, AB variant en Francais
Business
GM2-gangliosidosis, AB variant in the Marketplace Patents on GM2-gangliosidosis, AB variant
Experimental / Informatics
List of terms related to GM2-gangliosidosis, AB variant

GM2-gangliosidosis, AB variant is a rare inherited disorder that causes progressive destruction of nerve cells in the brain and spinal cord. It has a similar pathology to Sandhoff disease and Tay-Sachs disease.

Signs and symptoms of the AB variant begin in infancy. Infants with this disorder typically appear normal until the age of 3 to 6 months, when development slows and muscles used for movement weaken. Affected infants lose motor skills such as turning over, sitting, and crawling. As the disease progresses, infants develop seizures, vision and hearing loss, mental retardation, and paralysis. An eye abnormality called a cherry-red spot, which can be identified with an eye examination, is characteristic of this disorder. Children with the AB variant usually live only into early childhood.

Mutations in the GM2A gene cause GM2-gangliosidosis, AB variant. The GM2A gene provides instructions for making a protein called the GM2 activator. This protein is required for the normal function of beta-hexosaminidase A, a critical enzyme in the nervous system that breaks down a fatty substance called GM2 ganglioside. If mutations disrupt the activity of the GM2 activator, beta-hexosaminidase A cannot perform its normal function. As a result, GM2 ganglioside can accumulate to toxic levels in the brain and spinal cord. Progressive damage caused by the buildup of GM2 ganglioside leads to the destruction of nerve cells, which causes the severe medical problems characteristic of the AB variant. This condition is inherited in an autosomal recessive pattern.

GM2-gangliosidosis, AB variant

See also

Navigation menu